Amifostine can differentially modulate DNA double-strand breaks and apoptosis induced by idarubicin in normal and cancer cells by Wozniak, K. et al.
22 Experimental Oncology 30, 22–28, 2008 (March)
Idarubicin (Fig. 1, a) is an anthracycline antibiotic 
used in the treatment of acute leukaemias and other 
malignancies. Its primary anticancer effect is under-
lined by the ability to diffuse across the cellular mem-
brane and intercalation between DNA base pairs, tar-
geting topoisomerase II in proliferating cells, resulting 
in the induction of, usually lethal, DNA double-strand 
breaks (DSBs) [1–3]. Idarubicin may also generate 
reactive oxygen species (ROS), which contribute to 
its side effects in normal cells, especially in tissues, 
where free radical scavengers are scarce, e. g. heart 
[4, 5]. Apoptosis induced by the drug may be a conse-
quence of DNA damage. Idarubicin may induce either 
apoptotic death, like in human leukaemia cells or non-
apoptotic death, like in human MCF-7 breast tumour 
cells [1, 6, 7]. However, the molecular mechanism of 
idarubicin-induced cell death remains unclear.
Amifostine (Fig. 1, b) is a thiol derivative used to 
protect normal cells in chemo- and radiotherapy of 
numerous cancer including solid tumours, leukae-
mias and lymphomas [8]. It undergoes activation by 
the interaction with alkaline phosphatase, which is 
scarce in neoplastic cells. Therefore, different uptake 
of amifostine in normal and cancer cells may contrib-
ute to its diversity of action. Recently, we have shown 
that amifostine decreased the DNA-damaging effect 
of idarubicin in normal human lymphocytes, but in-
creased the effect in murine growth factor-dependent 
pro-B lymphoid cell line BaF3 expressing TEL/ABL, 
an oncogenic fusion tyrosine kinase [9]. Additionally, 
amifostine did not affect the action of idarubicin in 
p53-deficient HL-60 cells. Therefore, it seems that the 
action of amifostine could depend on the expression 
of proteins, which can be involved in the reaction of 
the cell to DNA-damaging agents, like p53. We have 
also shown that oncogenic tyrosine kinases, includ-
ing TEL/ABL, may stimulate DNA repair [10]. General 
mechanisms of the cytoprotective action of amifostine 
include stabilizing and protecting DNA by binding to it, 
scavenging of free radicals, forming of conjugates with 
electrophiles and reducing cell death [11–14].
In the present work we tried to take a closer look 
at the consequence of interaction of amifostine and 
idarubicin with DNA in normal and cancer cells. Be-
cause most chemotherapeutic agents exert cytotoxic 
effect via direct interaction with DNA, the mechanism 
of DNA damage and DNA repair should be primarily 
taken into account in searching for the mode of action 
of amifostine in cancer cells. Due to the great diversity 
of genetic changes in leukemias, it is unlikely that 
only one determines response of DNA to combined 
action of a chemotherapeutic agent and amifostine. 
One possible way to search for an insight into this 
problem is to choose leukemic cells with genetic ab-
errations connected with phenotypic features, which 
influence reaction of the cell to DNA damage. We 
chose normal human peripheral blood lymphocytes 
and myelogenous leukaemia K562 cells. The latter 
lack the p53 protein activity [15] and stably express 
the BCR/ABL oncogenic fusion tyrosine kinase, which 
can be involved in DSBs repair [10]. Additionally, K562 
cells were reported to be resistant to apoptosis [16]. 
We used pulse-field gel electrophoresis (PFGE) as the 
most reliable method for detection and repair of DSBs. 
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Apoptosis was evaluated by caspase-3 activity assay 
assisted by the alkaline comet assay to evaluate DNA 
fragmentation typical for apoptosis as well as DAPI 
staining of the cells for the detection of morphological 
changes in chromatin.
MATERIALS AND METHODS
Chemicals. Idarubicin (8-acetyl-10-[(3-amino-
2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-
7,8,9,10-tetrahydro-6,8,11-trihydroxy-(8S-cis)-5,12-
naphthacenedion) was obtained from Pharmacia and 
Upjohn (Milan, Italy). Amifostine (WR2721, S-2-(3-
aminopropylamino)-ethylphosphorothioic acid), RPMI 
1640 medium, fetal bovine serum (FBS), streptomycin, 
penicillin, phytohemagglutinin, low-melting point (LMP) 
and normal-melting point (NMP) agarose, phosphate 
buffered saline (PBS), DAPI (4’,6-diamidino-2-phenyl-
indole), ethidium bromide and Bradford reagent were 
purchased from Sigma (St. Louis, MO, USA). CleanCut 
agarose, proteinase K reaction buffer, proteinase K, 
TBE buffer and wash buffer to PFGE assay were ob-
tained from Bio-Rad (Hercules, CA, USA). ApoAlert 
Caspase Colorimetric Assay Kit was purchased from 
Clontech Laboratories Inc. (Palo Alto, CA, USA). All 
other chemicals were of the highest commercial grade 
available. 
Cells. Blood was obtained from young (20–31 
years old), male, healthy, non-smoking donors. 
Peripheral blood lymphocytes were isolated by cen-
trifugation (15 min, 280 × g) in a density gradient of 
Gradisol L. The lymphocytes were cultured in RPMI 
1640 medium with 2 mM L-glutamine supplemented 
with 20% heat-inactivated fetal bovine serum (FBS), 
streptomycin (100 µg/ml), penicillin (100 U/ml) and 
phytohemagglutinin (0.1 mg/ml) in the presence of a 
5% CO2 atmosphere at 37 °C. In the case of the lym-
phocytes each experiments was performed on the cells 
obtained from blood of three different donors. Human 
chronic myelogenous leukemia cells (K562 cells) were 
obtained from Prof. Jacques Robert of Department of 
Biochemistry, Institute Bergonie, Bordeaux, France. 
They were grown in RPMI 1640 medium with 2 mM 
L-glutamine supplemented with 10% heat-inactivated 
fetal bovine serum (FBS), streptomycin (100 µg/ml) 
and penicillin (100 U/ml) in the presence of a 5% CO2 
atmosphere at 37 °C.
Pulse-field gel electrophoresis (PFGE). The 
cells were pre-incubated with amifostine at 14 mM 
for 15 min and then exposed for 1 h to idarubicin at 
concentrations from the range 0.05–50 µM at 37 °C 
in RPMI 1640 medium without serum and antibiotic 
supplementation. An aliquot of 5 × 106 cells/ml after 
treatment was washed by centrifugation (1000 × g, 
5 min, 4 °C) and mixed with 2% CleanCut agarose to 
a final concentration of 0.75% at 50 °C. The cells/aga-
rose mixture was transferred to plugs moulds. After 
solidifying agarose plugs were lysed with proteinase 
K in a proteinase K reaction buffer and were incubated 
overnight at 50 °C. After lysis plugs were washed four 
times in 1 × wash buffer and stored at 4 °C in this buf-
fer. Washed plugs were inserted into the wells of a 
0.8% agarose gel prepared in 0.5 × TBE buffer. The 
gel was then placed horizontally in the gel box of the 
contour-clamped homogeneous electric field gel 
electrophoresis apparatus CHEF II (Bio-Rad) with 
120° angle between fields. The voltage was 4 V/cm 
and the time-pulse gradient was 1–500 s for 60 h and 
1500–1600 s for 31 h at 14 °C. After electrophoresis 
the gel was stained with 1 µg/ml ethidium bromide 
and examined under UV light. DNA concentration in 
samples before and after electrophoresis was deter-
mined using an Agilent spectrophotometer, model 
8453 Hewlett Packard (Waldbronn, Germany). DNA 
double-strand breaks were measured as the fraction 
of activity released (FAR; ratio of DNA released in an 
electrophoretic band and total DNA) [17].
To examine DSBs repair using PFGE assay, the 
cells after treatment with idarubicin at 0.5 µM for 1 h, 
as well as control cells, were washed and resuspended 
in a fresh RPMI 1640 medium with 14 mM amifostine. 
Aliquots of the cell suspension were taken immediately 
and 30, 60 and 120 min later. The samples were then 
processed as described above.
Alkaline comet assay. The alkaline version of the 
comet assay was performed essentially according to 
the procedure of Singh et al [18] as described previ-
ously [9]. The cells were pre-incubated with amifostine 
at 14 mM for 15 min and then incubated for 12 h with 
idarubicin at concentrations from the range 0.05–50 
µM at 37 °C in RPMI 1640 medium with serum and 
antibiotics supplementation. A freshly prepared sus-
pension of the cells (1–3 × 105 cells/ml) in 0.75% LMP 
agarose dissolved in PBS was spread onto microscope 
slides pre-coated with 0.5% normal agarose. The cells 
were then lysed for 1 h at 4 °C in a buffer consisting of 
2.5 M NaCl, 100 mM EDTA, 1% Triton X-100, 10 mM 
Tris, pH 10. After the lysis, the slides were placed in an 
electrophoresis unit, DNA was allowed to unwind for 
20 min in the solution containing 300 mM NaOH and 
1 mM EDTA, pH > 13. Electrophoresis was conducted 
in the electrophoretic solution containing 30 mM NaOH 
and 1 mM EDTA, pH > 13 at ambient temperature of 
4 °C for 20 min at electric field strength 0.73 V/cm 
(28 mA). The slides were then neutralized with 0.4 M 
Tris, pH 7.5, stained with 2 µg/ml DAPI and covered 
with cover slips. 
The slides were observed at 200 × magnification 
in a Eclipse fluorescence microscope (Nikon, Tokyo, 
Japan) attached to a COHU 4910 video camera (Cohu, 
San Diego, CA, USA) equipped with an UV filter block 
consisting of an excitation filter (359 nm) and a barrier 
filter (461 nm) and connected to a personal computer-
based image analysis system Lucia-Comet v. 4.51 
(Laboratory Imaging, Praha, Czech Republic). Fifty 
images were randomly selected from each sample and 
the percentage of DNA in the comet tail was measured. 
Two parallel tests with aliquots of the same sample of 
cells were performed for a total of 100 cells and the 
mean percentage of DNA in the comet tail was calcu-
lated. The percentage of DNA in the comet tail is posi-
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tively correlated with the level of DNA breakage in a cell 
and its mean value from all samples in each experiment 
was taken as an index of DNA fragmentation. 
DAPI nuclear staining assay. The cells were 
pre-incubated with amifostine at 14 mM for 15 min 
and then incubated for 12 h to idarubicin at concentra-
tions from the range 0.05–50 µM at 37 °C in RPMI 1640 
medium with serum and antibiotics supplementation. 
After treatment the cells were washed with PBS and 
mixed with DAPI at a final concentration of 50 ng/ml. 
After 30 min of staining, the cell samples were placed 
on glass slides and covered with cover slips. Apop-
totic chromatin condensation was observed under the 
Eclipse fluorescence microscope. The changes in a 
chromatin condensation were evaluated qualitatively 
in 100 cells. The experiment was prepared one time. 
Caspase-3 activity. The cells were pre-incu-
bated with amifostine at 14 mM for 15 min and then 
incubated with idarubicin at concentrations from 
the range 0.5–20 µM for 48 h at 37 °C in RPMI 1640 
medium with serum and antibio tics supplementation. 
An aliquot of cell suspension (2 × 106/ml) after treat-
ment was washed with PBS and centrifuged (400 × g, 
10 min, 4 °C). The cells were then lysed in 50 µl lysis 
buffer (ApoAlert Caspase Colorimetric Assay Kit). 
Undissolved proteins and nuclei were removed by 
centrifugation at 1000 × g for 3 min at 4 °C. 50 µl of 
aliquots of 2 × reaction buffer/DTT mix and 5 µl of 
1 mM caspase-3 substrate (DEVD-pNA) were added 
to supernatants to a final concentration of 50 µM and 
final mixtures were incubated at 37 °C for 60 min. The 
samples were read at 405 nm with calibration against 
a standard linear regression curve of p-nitroaniline 
(pNa). Caspase activity was defined as nmol pNA 
released per hour per mg of protein (nmol/h/mg pro-
tein). The protein concentration was determined using 
Bradford reagent.
Data analysis. The data were analysed using 
Statistica package (StatSoft, Tulsa, OK, USA). If 
no significant differences between variations were 
found, as assessed by Snedecor-Fisher test, the dif-
ferences between means were evaluated by applying 
the Student’s t-test. Otherwise, the Cochran-Cox test 
was used. 
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Fig. 1. Chemical structure of idarubicin (a) and amifostine (b)
RESULTS
Effect of amifostine on idarubicin-induced 
DSBs and their repair 
Fig. 2 shows DNA damage measured by PFGE in 
lymphocytes (a) and K562 cells (b) pre-treated with 
amifostine at 14 mM for 15 min and then exposed for 
1 h to idarubicin in comparison with the cells treated 
with idarubicin singly. Idarubicin induced DSBs in a 
dose-independent manner. In the case of lymphocytes 
we observed the highest level of DSBs after incubation 
with idarubicin at 0.5 µM (Fig. 2, a, lane 2), in K562 
cells the maximum was reached after incubation with 
idarubicin at 5 µM (Fig. 2, b, lane 3). Amifostine exerted 
different effect on this type of DNA damage in idarubi-
cin-treated normal and cancer cells: it decreased the 
level of DNA damage in lymphocytes and it increased 
the extent of DNA damage in K562 cells. We also cal-
culated the values of FAR for the control cells and the 
cells pre-incubated with amifostine, which confirmed 
our observations (Fig. 3).
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Fig. 2. PFGE assay of DNA double strand breaks in lymphocytes 
(a) and K562 cells (b) after treatment with amifostine and idarubi-
cin. M — S. pombe molecular weight marker (Mbp); 1 — control; 
2–4 — idarubicin at 0.5, 5 and 50 µM, respectively; 5 — amifos-
tine at 14 mM; 6–8 — 14 mM amifostine with idarubicin at 0.5, 5 
and 50 µM, respectively
Fig. 4 presents DNA damage in lymphocytes (a) 
and K562 cells (b) immediately after exposure to idaru-
bicin at 0.5 µM as well as 30, 60 and 120 min thereafter. 
Post-incubation was performed in the presence of 
amifostine at 14 mM. In the case of the lymphocytes, 
the level of DNA damage in the control cells (Fig. 4, a, 
lanes 1–4) and in the cells post-incubated in the pres-
ence of amifostine (Fig. 4, a, lanes 5–7) was very low. 
Lymphocytes exposed to idarubicin at 0.5 µM did not 
repair DSBs during a 120-min post-treatment incuba-
tion (Fig. 4, a, lanes 8–11). However, in the presence of 
14 mM amifostine we observed a significant decrease 
(P < 0.001) of DNA damage during repair incubation 
in lymphocytes (Fig. 4, a, lanes 12–14). In the case 
of control K562 cells (Fig. 4, b, lanes 1–4) and the 
cells post-incubated with amifostine (Fig. 4, b, lanes 
5–7), we detected a high level of DNA fragmentation. 
Therefore, the preparation of these cells must have 
introduced damage to their DNA. Additionally, we cal-
culated the values of FAR for the control cells and the 
cells post-incubated with amifostine, which confirmed 
our observations (Fig. 5). Similarly to lymphocytes, 
K562 cells exposed to idarubicin at 0.5 µM did not re-
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pair DSBs during a 120-min post-treatment incubation 
(Fig. 4, b, lanes 8–11). In the presence of amifostine 
at 14 mM, we observed an increase in the level of DNA 
fragmentation for 60 and 120 min of repair incubation 
(Fig. 4, b, lanes 13–14) (less DNA in samples incubated 
during repair with amifostine for 60 and 120 than in 
samples incubated without amifostine). 
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Fig. 3. DNA damage measured as fraction of activity released 
(FAR) in PFGE assay in lymphocytes (a) and K562 cells (b) 
exposed at 37 °C to idarubicin in the absence ( ) or in the pres-
ence ( ) of 14 mM amifostine. Regression lines were calculated 
by the means of the least square methods. Figures next to each 
curve indicate the regression coefficiant (R) for that curve. Er-
ror bars denote SD. Data presented are mean results from two 
independent experiments. *P < 0.05, **P < 0.001.
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Fig. 4. PFGE assay of DNA double strand breaks in lymphocytes 
(a) and K562 cells (b) after various time of repair incubation of 
idarubicin-induced DNA damage in the presence of 14 mM amifos-
tine. M — S. pombe molecular weight marker (Mbp); 1–4 — con-
trol at 0, 30, 60 and 120 min, respectively; 5–7 — 14 mM amifostine 
at 30, 60 and 120 min, respectively; 8–11 — 0.5 µM idarubicin at 0, 
30, 60 and 120 min, respectively; 12–14 — 14 mM amifostine and 
0.5 µM idarubicin at 30, 60 and 120 min, respectively
Effect of amifostine on apoptotic DNA fragmen-
tation and chromatin condensation induced by ida-
rubicin. The comet assay can be applied to distinguish 
apoptotic from non-apoptotic cells on the basis of their 
characteristic image and DNA fragmentation pattern 
[19]. Apoptotic cells form structures with fan-like tails 
and small heads, as normal or less damaged cells 
form smaller structures with large heads and narrow 
tails. Idarubicin induced apoptotic DNA fragmentation 
and chromatin condensation in both types of the cells 
(Fig. 6). At the maximal used concentration of idaru-
bicin, 50 µM, we observed majority of such changes 
in K562 cells (Fig. 6, b). The changes observed were 
less pronounced in the lymphocytes exposed to ida-
rubicin, especially at 0.5 and 5 µM, in the presence of 
amifostine in comparison with the cells incubated with 
idarubicin only (Fig. 6, a). In K562 cells we observed an 
increase of the cell number with chromatin condensa-
tion and apoptotic DNA fragmentation after co-treat-
ment with idarubicin and amifostine (Fig. 6, b).
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Fig. 5. Time course of the repair of DNA damage in human lym-
phocytes (a) and K562 cells (b) treated with idarubicin at 0.5 μM 
in the absence (∇) or in the presence ( ) of 14 mM amifostine 
compared with untreated control ( ) and amifostine alone ( ) 
and evaluated by PFGE assay. Regression lines were calculated 
by the means of the least square methods. Figures next to each 
curve indicate the regression coefficiant (R) for that curve. Er-
ror bars denote SD. Data presented are mean results from two 
independent experiments
Effect of amifostine on idarubicin-induced 
activity of caspase-3. The activation of caspase-3 
was determined by the cleavage of specific substrate 
(DEVD-pNA) and the product of the cleavage was 
measured by a colorimetric assay. After 48-h incuba-
tion idarubicin increased the rate of the activation of 
caspase-3 in the lymphocytes and K562 cells (Fig. 7). 
Amifostine at 14 mM decreased this rate in normal cells 
in the case of idarubicin at 5 µM and 50 µM (P < 0.05 
and P < 0.01, respectively, Fig. 7, a) and increased 
it in cancer cells after incubation with the drug at 
0.5 µM and 5 µM (P < 0.01 and P < 0.05, respectively, 
Fig. 7, a). 
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Fig. 6. DNA fragmentation (white bars) and apoptotic morphological 
changes in chromatin (black bars) in lymphocytes (a) and K562 cells 
(b) exposed to idarubicin without or with amifostine at 14 mM. Apoptotic 
changes in chromatin were evaluated qualitatively into 100 cells with a 
fluorescent microscope after staining with DAPI. DNA fragmentation 
was evaluated into 100 cells by the alkaline comet assay
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Fig. 7. Effect of amifostine on idarubicin-induced activity of cas-
pase-3 in the lymphocytes (a) and K562 cells (b). The cells were 
incubated with idarubicin in the absence (○) or in the presence of ami-
fostine at 48 h (○). Activity of caspase-3 was determined by ApoAlert 
Caspase Colorimetric Assay as described in the text. Regression lines 
were calculated by the means of the least square methods. Figures 
next to each curve indicate the regression coefficiant (R) for that 
curve. Error bars denote SD. Data presented are mean results from 
three independent experiments. *P < 0.05, **P < 0.01.
DISCUSSION
The primary mode of action of idarubicin underly-
ing its anti-tumour activity is interaction with topoi-
somerase II leading to continuous production of DSBs 
in proliferating cells. Metabolism of idarubicin in the 
cell can also lead to the production of reactive oxygen 
species (ROS), which can damage DNA [4, 5]. The 
accumulation of unrepaired DNA damage may in-
duce the process of apoptotic cell death. It is unclear 
whether the generation of ROS is actually associated 
with the apoptotic process induced by idarubicin. We 
observed that idarubicin induced DSBs in both types 
of cells, normal lymphocytes and leukaemia K562 
cells (Fig. 2). Because we used non-proliferating lym-
phocytes, we presume that DSBs, which we observed 
by PFGE assay, resulted from the action of ROS rather 
than of topoisomerase II. DNA damage observed at low 
concentration of idarubicin in lymphocytes could be 
related to the action of ROS. Similarly, the clear action 
of amifostine in lymphocytes in contrast to K562 cells 
(Fig. 2) might indicate on ROS-mediated mechanism of 
DNA damaging. These DNA lesions were not repaired 
in either kind of cells (Fig. 3). Amifostine modulated the 
DNA-damaging potential of idarubicin. In lymphocytes 
pre-incubated with amifostine we observed decrease in 
the level of DSBs (Fig. 2, a, lanes 6–8). It was shown that 
amifostine might decrease the DNA-damaging potential 
of idarubicin through formation of conjugates with it 
and scavenging ROS induced by idarubicin [5, 13, 20]. 
Amifostine may also decrease the amount of this type of 
DNA damage, arising from inactivation of topoisomer-
ase II, in proliferating cells [2]. In contrast with normal 
cells, amifostine caused increase in the level of DSBs 
in K562 cells (Fig. 2, b, lanes 6–8). We speculate that 
this effect, in part, could result from different uptake of 
amifostine in normal and cancer cells [8]. 
We showed that amifostine could modulate the 
extent of DNA fragmentation induced by idarubicin in 
K562 cells (Fig. 4, b, lanes 12–14). It is possible by its 
interaction with DNA repair proteins [21, 22]. 
High molecular weight DNA fragments resulting from 
DSBs are characteristic to the early stage of apoptosis. 
We observed that idarubicin apart from induction such 
DNA fragmentation, caused morphological changes in 
chromatin (Fig. 6) and increased activity of caspase-3 
(Fig. 7) in normal and cancer cells. These changes are 
associated with apoptosis [19, 23–25]. Idarubicin and 
other anthracyclines can activate caspases in the re-
sponse to DNA damage or through oxidative stress and 
mitochondrial membrane potential collapse [26, 27]. 
However, it was shown that the generation of ROS is not 
involved in idarubicin-induced apoptosis in human leu-
kaemia cells [28]. Moreover, recent data have shown that 
caspase-3/7 may be dispensable for idarubicin-induced 
internucleosomal DNA cleavage during apoptosis in hu-
man leukaemia cells [29]. Our results indicate that the 
level of idarubicin-induced DSBs correlate with apoptotic 
DNA fragmentation, chromatin condensation as well as 
activation of caspase-3. These effects were esspecially 
pronounced in K562 cells, where more cells with apop-
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totic DNA fragmentation and chromatin condensation 
in comparison to normal cells were observed (Fig. 6). 
Interestingly, amifostine reduced DNA fragmentation 
and chromatin morphological changes (Fig. 6, a) and 
decreased caspase-3 activity (Fig. 7, a) in lymphocytes. 
Similar effects were also reported previously [30, 31]. The 
activation of caspase-3 can course via H2O2-mediated 
mechanism in cells incubated with amifostine.
In K562 cells, amifostine in combination with ida-
rubicin increased not only the level of DSBs, but also 
cellular changes typical for apoptosis [32]. However 
it was also observed that the continuous exposure 
of a human myelodysplastic cell line to amifostine 
was cytotoxic and associated with an induction of 
apoptosis independent of alterations in p53 expres-
sion [33]. In our previously studies we showed that 
amifostine increased the viability of murine growth 
factor-dependent pro-B lymphoid cells BaF3 and their 
BCR/ABL-transformed counterparts [34]. 
The results obtained suggest that amifostine can dif-
ferentially modulate DSBs and apoptosis induced by ida-
rubicin in normal and cancer cells. It can protect normal 
cells against drug-induced such DNA damage and it can 
potentate the action of the drug in leukaemic cells. Taking 
into account the genetic constitution of the cells, which 
we used in these studies, we can speculate that different 
response to amifostine might follow from the interaction 
between amifostine and BCR/ABL protein and interaction 
between caspase-3 and BCR/ABL protein. 
Further studies on link between amifostine-induced 
modulation of DSBs and apoptosis of cancer cells will 
bring a deeper insight into molecular mechanism of 
amifostine action.
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АМИФОСТИН МОЖЕТ ДИФФЕРЕНЦИАЛЬНО МОДУЛИРОВАТЬ 
ДВУХНИТЕВЫЕ РАЗРЫВЫ ДНК И АПОПТОЗ, ВЫЗВАННЫЙ 
ИДАРУБИЦИНОМ В НОРМАЛЬНЫХ И ОПУХОЛЕВЫХ КЛЕТКАХ
Ранее нами было показано, что амифостин дифференциально модулирует ДНК-повреждающее действие идарубицина в 
нормальных и злокачественных клетках, и что наличие белка р53 и онкогенных тирозин киназ может иметь значение для 
этих различий. Цель: изучить влияние амифостина на идарубицин-опосредованные двухнитевые разрывы ДНК (DSBs) 
и апоптоз. Методы: мы применили гель-электрофорез в пульсирующем поле (PFGE) для выявления DSBs и изучения 
их репарации в нормальных лимфоцитах человека и клетках K562 хронической миелоидной лейкемии, у которых р53 
неактивен и экспрессирована BCR/ABL-тирозин киназа. Апоптоз оценивали с помощью реактивов для выявления 
активности каспазы-3, проведения щелочного гель-электрофореза одиночных клеток и DAPI-окрашивания. Результаты: 
идарубицин вызывает образование DSBs в нормальных и злокачественных клетках независимо от дозы. Оба типа клеток не 
репарировали эти повреждения за 120 мин, при этом амифостин дифференциально молулировал уровень DSBs — уменьшал 
в лимфоцитах и увеличивал в K562-клетках. В отличие от контрольных клеток амифостин потенциировал апоптическую 
фрагментацию ДНК, конденсацию хроматина и активность каспазы-3 в лейкемических клетках. Выводы: амифостин может 
дифференциально модулировать DSBs и апоптоз, вызванные идарубицином в нормальных и злокачественных клетках. Он 
может защитить нормальные клетки от повреждения ДНК, вызванного химиопрепаратом, и в то же время потенциировать 
действие препарата на лейкемические клетки. Дальнейшие исследования связи между вызванной амифостином модуляцией 
DSBs и апоптоза опухолевых клеток позволит лучше понять молекулярные механизмы действия амифостина.
Ключевые слова: ДНК репарация, двухнитевые разрывы ДНК, амифостин, идарубицин, лейкемия, апоптоз.
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